AU2002334387B2 - Antigen presenting cells, method for their preparation and their use for cancer vaccines - Google Patents

Antigen presenting cells, method for their preparation and their use for cancer vaccines Download PDF

Info

Publication number
AU2002334387B2
AU2002334387B2 AU2002334387A AU2002334387A AU2002334387B2 AU 2002334387 B2 AU2002334387 B2 AU 2002334387B2 AU 2002334387 A AU2002334387 A AU 2002334387A AU 2002334387 A AU2002334387 A AU 2002334387A AU 2002334387 B2 AU2002334387 B2 AU 2002334387B2
Authority
AU
Australia
Prior art keywords
cells
pbmc
cta
cancer
adhapi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002334387A
Other languages
English (en)
Other versions
AU2002334387A1 (en
Inventor
Rita De Santis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EPIGEN THERAPEUTICS Srl
Original Assignee
Epigen Therapeutics Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigen Therapeutics Srl filed Critical Epigen Therapeutics Srl
Publication of AU2002334387A1 publication Critical patent/AU2002334387A1/en
Application granted granted Critical
Publication of AU2002334387B2 publication Critical patent/AU2002334387B2/en
Assigned to EPIGEN THERAPEUTICS S.R.L. reassignment EPIGEN THERAPEUTICS S.R.L. Request for Assignment Assignors: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002334387A 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines Expired AU2002334387B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2001282503 2001-07-30
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (2)

Publication Number Publication Date
AU2002334387A1 AU2002334387A1 (en) 2003-05-29
AU2002334387B2 true AU2002334387B2 (en) 2007-10-04

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002334387A Expired AU2002334387B2 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Country Status (16)

Country Link
US (3) US20030119187A1 (enExample)
EP (1) EP1412485B1 (enExample)
JP (1) JP2004536615A (enExample)
KR (1) KR100916670B1 (enExample)
CN (1) CN100591762C (enExample)
AT (1) ATE505533T1 (enExample)
AU (1) AU2002334387B2 (enExample)
BR (1) BR0211520A (enExample)
CA (1) CA2453522C (enExample)
DE (1) DE60239741D1 (enExample)
DK (1) DK1412485T3 (enExample)
ES (1) ES2367256T3 (enExample)
HU (1) HUP0401753A3 (enExample)
MX (1) MXPA04000885A (enExample)
PL (1) PL211907B1 (enExample)
WO (2) WO2003012085A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN1910284B (zh) * 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
JP4925033B2 (ja) * 2004-02-03 2012-04-25 学校法人 久留米大学 ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
WO2011072088A2 (en) * 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
JP6082737B2 (ja) * 2011-07-07 2017-02-15 リサーチ キャンサー インスティテュート オブ アメリカＲｅｓｅａｒｃｈ Ｃａｎｃｅｒ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ａｍｅｒｉｃａ がんを治療するためのシステム、方法、および製剤
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
PT2914254T (pt) * 2012-10-30 2020-04-02 Mei Pharma Inc Terapias de combinação para tratar cancros quimiorresistentes
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185811A (zh) * 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
NZ503334A (en) * 1997-09-15 2002-05-31 Genetic Immunity Llc A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Moldenhauer et al, Blood, 96: 118a, 2000 (cited in the ISR) *
Roddie et al, Blood, 96: 707a, 2000 (cited in the ISR) *
Schichijo et al, Jpn J Cancer Res, 87: 751-756, 1996 (cited in the ISR) *

Also Published As

Publication number Publication date
US20050002920A1 (en) 2005-01-06
HK1068913A1 (zh) 2005-05-06
ATE505533T1 (de) 2011-04-15
MXPA04000885A (es) 2004-06-03
PL211907B1 (pl) 2012-07-31
WO2003012086A1 (en) 2003-02-13
BR0211520A (pt) 2004-09-14
JP2004536615A (ja) 2004-12-09
HUP0401753A2 (hu) 2004-11-29
EP1412485A1 (en) 2004-04-28
EP1412485B1 (en) 2011-04-13
CA2453522A1 (en) 2003-02-13
WO2003012085A1 (en) 2003-02-13
KR100916670B1 (ko) 2009-09-08
US20040185563A1 (en) 2004-09-23
CN1537161A (zh) 2004-10-13
DE60239741D1 (de) 2011-05-26
US20030119187A1 (en) 2003-06-26
US7883889B2 (en) 2011-02-08
PL367617A1 (en) 2005-03-07
CA2453522C (en) 2013-04-30
HUP0401753A3 (en) 2011-04-28
KR20040021662A (ko) 2004-03-10
ES2367256T3 (es) 2011-10-31
DK1412485T3 (da) 2011-08-01
CN100591762C (zh) 2010-02-24

Similar Documents

Publication Publication Date Title
CA2453522C (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
AU2002334387A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
RU2313365C2 (ru) Фармацевтическая композиция для индукции иммунной реакции у человека
AU2003261546B2 (en) A cell therapy method for the treatment of tumors
DK2016930T3 (en) CD8 cell suspension for use in the treatment of melanomas
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CA2367590A1 (en) In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
Kalady et al. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
Piemonti et al. Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability
HK1068913B (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
CN100558400C (zh) 诱导人或动物免疫应答的药物组合物
Triozzi et al. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma
Cha MARRYING IMMUNOTHERAPY AND CHEMOTHERAPY: A CANCER THERAPY BASED ON T LYMPHOCYTE EXPANSION AUGMENTED BY ALTERNATE GAMMA CHAIN CYTOKINES AND GEMCITABINE-MEDIATED INHIBITION OF MYELOID DERIVED SUPPRESSOR CELLS
WO2007025705A2 (en) Method for the generation of antigen-specific t-cells and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EPIGEN THERAPEUTICS S.R.L.

Free format text: FORMER OWNER WAS: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired